How properly did payers present “honest” entry insurance policies? Primarily based on an current ICER report titled “Evaluation of Limitations to Honest Entry“, the headline figures appear fairly good:
Total charges of concordance with ICER’s standards have been 70% for value sharing of fairly-priced medication, 96% for medical eligibility standards, 98% for step remedy, and 100% for supplier restrictions
At first look, this looks like very reasonable entry. Nevertheless, digging a bit deeper, exhibits that sufferers do nonetheless face important hurdles.
The desk beneath exhibits that whereas 70% of medication obtained honest entry, that is based mostly on the 84 medication that have been truly lined by insurance coverage. Of the 342 medication evaluated, nevertheless, most medication (75%, 258 out of 342) weren’t lined in any respect. De facto, this imply that value sharing was 100%! If we embrace each lined and non-covered medication within the evaluation, then value sharing could be thought-about honest based mostly on ICER’s standards solely 17.4% (n=59 out of 352) of the time.
Payers have been extra prone to observe ICER guidelines with respect to medical eligibility and limitations on step remedy, and supplier restrictions. Nevertheless, a few of these equity standards characterize a comparatively low bar. As an example, ICER states that they’ve applied “a most variety of three steps allowed for a step remedy coverage to stay concordant with honest entry standards”. Requiring sufferers to step by way of 2 not to mention 3 therapies, nevertheless, is very problematic for a lot of ailments.
Briefly, do US business payers present honest entry? The reply to this query probably will depend on the attention of the beholder.
